Advanced Filters
noise

Peking, China Clinical Trials

A listing of Peking, China clinical trials actively recruiting patients volunteers.

Found 2,907 clinical trials
J Jialin Zhu, MD

Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy

Allogeneic hematopoietic stem cell transplantation is the only curative treatment for malignant hematologic diseases. However, immune rejection is a major limitation in its application. In the "Beijing Protocol", the use of granulocyte colony-stimulating factor (G-CSF) in combination with anti-thymocyte globulin (ATG) can achieve "everyone has a donor". The use of …

18 years of age All Phase N/A
y yajing zhang, MD/PhD

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.

18 - 65 years of age All Phase 1
K Kaijiang Kang, MD

TaVNS for Acute Intracerebral Hemorrhage

This study aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with acute intracerebral hemorrhage (ICH). The taVNS intervention will be delivered using the BS-TVNS800-1 transcutaneous electrical stimulation therapy device (KERFUN, Shanxi, China). A total of 186 patients will be randomly assigned in …

18 - 80 years of age All Phase N/A
Y Yan Xue, Doctor

JS207 Combination Therapy in Triple-negative Breast Cancer

This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.

18 - 75 years of age All Phase 2
M Ming Yang, Ph.D

Drug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis

This investigation is a prospective, multicenter, randomized controlled, non-inferiority clinical trial, to evaluate the safety and efficacy of the investigational device against alternative models/specifications of the control device. The study will be conducted across multiple Chinese centers, with planned enrollment of 224 patients with symptomatic intracranial atherosclerotic stenosis. Subjects meeting …

18 - 80 years of age All Phase 3
Y Yufei Gao

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.

18 years of age All Phase 1
H Huaiwu He

Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism

The goal of this observational study is to compare the consistency of saline contrast Electrical Impedance Tomography(EIT) method and Computed Tomography Pulmonary Angiography (CTPA) in diagnosing acute pulmonary embolism. The main question it aims to answer is: Can bedside saline contrast EIT method be used for the diagnosis of acute …

18 years of age All Phase N/A
C Chenlong YANG, M.D., Ph.D.

Allogeneic γδT Cells in Glioblastoma

This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual …

18 - 70 years of age All Phase N/A
L Luyan Shen

Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests after surgery, first in 3-7 days and second in 1 month after surgery. And patients who confirm two-round landmark undetectable MRD will …

18 years of age All Phase N/A
C ChengYan Deng, Doctor of Medicine

A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia

18 - 45 years of age Female Phase 3

Simplify language using AI